BACKGROUND: Preeclampsia affects approximately 1 in 10 pregnancies, leading to severe complications and long-term health ...

Incyte’s phase 3 STOP-HS data show that povorcitinib improved symptoms of moderate to severe hidradenitis suppurativa in most ...

Historically good results with IL-4 inhibitors raise questions with U.S. audience ...

Zura Bio (ZURA) stock update: tibulizumab enters Phase 2 for HS/SSc, cash runway to 2028, and key differentiation risks.

A 12-week pilot study found the Wim Hof method and a lifestyle program reduced key markers of inflammation in MS.

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

Cue Biopharma, Inc. ( CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases April 7, 2026 10:00 AM EDT Lucinda Warren - Interim CEO, Interim President,Principal ...

Researchers have established a direct experimental link between inflammatory signals in the intestinal lining and the kind of ...

A collaborative effort between researchers at the Henan Academy of Innovations in Medical Science, Zhengzhou University, and ...

A collaborative effort between researchers at the Henan Academy of Innovations in Medical Science, Zhengzhou University, and ...

71.4% and 69.2% of patients treated with zasocitinib achieved a static Physician Global Assessment (sPGA) score of 0/1 versus placebo (10.7% and 12.6%) and apremilast (32.1% and 29.7%) at week 16 (p<0 ...